SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2183484

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2183484

Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, IFA, Western Blot), Specimen (Blood, Saliva), Application (Infectious Diseases, Endocrinology, Cardiology), End User (Hospital, Blood Bank) & Region - Global Forecast to 2031

PUBLISHED:
PAGES: 481 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

The global immunoassay market is estimated to be valued at USD 31.65 billion in 2026 and is projected to reach USD 44.49 billion by 2031, registering a CAGR of 7.0% during the forecast period.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD billion)
SegmentsBy Product, By Technology, By Specimen, By Application, By End User, Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa

Market growth is primarily driven by the rising prevalence of chronic and infectious diseases, continued technological advancements in immunoassay systems, supportive government initiatives, and increasing demand for drug and alcohol screening driven by stringent regulatory requirements.

Immunoassay Market - IMG1

"By product, the reagents & kits segment accounted for the largest share of the immunoassay market in 2025."

Based on product type, the global immunoassay market is segmented into reagents & kits and analyzers. Among these, reagents & kits are expected to account for the largest share of the market, primarily owing to their recurring use across a broad range of diagnostic applications. The growing volume of immunoassay testing, coupled with the continuous requirement for consumable reagents and kits, supports sustained demand for this segment. In addition, the increasing availability of high-performance products that offer enhanced diagnostic accuracy, reliability, and workflow efficiency is contributing to their widespread adoption and supporting segment growth.

"By technology, the chemiluminescence immunoassay segment is expected to grow at a considerable rate during the forecast period."

The immunoassay market is segmented by technology into ELISA, chemiluminescence immunoassay (CLIA), immunofluorescence assay (IFA), rapid tests, ELISpot, western blotting, and other technologies. Among these, the CLIA segment is expected to grow significantly during the forecast period, driven by its increasing adoption in diagnosing and monitoring chronic and infectious diseases. CLIA offers several advantages over conventional techniques, including high sensitivity and specificity, a broad dynamic range, faster turnaround times, and lower background interference. These benefits, along with its suitability for automated and high-throughput testing, are expected to support the increasing adoption of CLIA in clinical diagnostic applications.

"Asia Pacific is expected to register the fastest growth rate in the immunoassay market between 2026 and 2031."

The global immunoassay market is segmented geographically into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Among these regions, Asia Pacific is expected to register the highest growth during the 2026-2031 forecast period. This growth is attributed to the region's large and expanding patient population, increasing prevalence of chronic and infectious diseases, growing awareness of early disease diagnosis, and continued improvements in healthcare infrastructure. In addition, increasing healthcare investments and the adoption of advanced diagnostic technologies across countries such as China, India, and Southeast Asian nations are expected to further support market growth in the region.

The breakdown of primary participants in the immunoassay market is as follows:

  • By Company Type: Tier 1 (32%), Tier 2 (41%), and Tier 3 (27%)
  • By Designation: C-level Executives (30%), Directors (26%), and Others (44%)
  • By Region: North America (53%), Europe (21%), Asia Pacific (17%), Latin America (6%), and the Middle East & Africa (4%)

Key players in the immunoassay market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), PerkinElmer, Inc. (US), Becton, Dickinson and Company (US), DiaSorin S.p.A. (Italy), Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), bioMerieux (France), QIAGEN N.V. (Germany), Sysmex Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), Agilent Technologies (US), Merck KGaA (Germany), Meridian Bioscience (US), Bio-Techne (US), Cellabs (Australia), Abnova Corporation (Taiwan), J. Mitra & Co. Pvt. Ltd. (India), Tosoh Corporation (Japan), Cell Sciences (US), Enzo Biochem (US), Creative Diagnostics (US), Boster Biological Technology (US), Elabscience (US), WAK-Chemie Medical GmbH (Germany), SeraCare (US), Epitope Diagnostics Inc. (US), Kamiya Biomedical Company (US), Gyros Protein Technologies (Sweden), Trivitron Healthcare (India), InBios International Inc. (US), and Maccura Biotechnology Co., Ltd. (China).

Research Coverage:

This research report categorizes the immunoassay market by product (reagents & kits and analyzers), specimen type (blood, urine, saliva, and other specimens), technology (enzyme-linked immunosorbent assays, rapid tests, chemiluminescence immunoassay, immunofluorescence assay, enzyme-linked immunospot, western blotting, and other technologies), application (infectious diseases, blood screening, oncology, endocrinology, bone and mineral disorders, autoimmune disorders, cardiology, drug monitoring and testing, allergy diagnostics, newborn screening, and other applications), end user (clinical laboratories, hospitals & clinics, blood banks, and home care settings), and region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America).

The report covers detailed information on major factors, such as drivers, restraints, opportunities, and challenges influencing immunoassay market growth. A detailed analysis of key industry players provides insights into their business overview, solutions, and key strategies, including partnerships, collaborations, expansions, agreements, product launches, and recent market developments. This report covers the competitive analysis of upcoming startups in the immunoassay ecosystem.

Reasons to Buy This Report:

The report will help leaders/new entrants in this market by providing revenue estimates for the overall immunoassay market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

  • Analysis of key drivers (increasing incidence of chronic and infectious diseases, increased demand for blood donations in healthcare systems and surgical procedures, growth in biotechnology and biopharmaceutical industries, supportive government regulatory policies and initiatives, increasing adoption of immunoassay-based POC and rapid testing, and increasing consumption of drugs, alcohol, and cannabis), restraints (stringent requirements for approval of immunoassay instruments and consumables and technical hurdles of immunoassay kits), opportunities (increasing growth opportunities in emerging economies, focus on companion diagnostics, development of condition-specific biomarkers and tests, integration of microfluidics in immunoassays, and improving immunoassay diagnostic technologies), and challenges (design challenges and low quality of antibodies and dearth of skilled professionals) influencing the immunoassay market growth.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the immunoassay market.
  • Market Development: Comprehensive information about lucrative markets; the report analyzes the immunoassay market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the immunoassay market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), and Bio-Rad (US), among others, in the immunoassay market.
Product Code: MD 4751

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
  • 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
  • 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 IMMUNOASSAY MARKET OVERVIEW
  • 3.2 IMMUNOASSAY MARKET, BY PRODUCT, 2026 VS. 2031
  • 3.3 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2026 VS. 2031
  • 3.4 IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2026 VS. 2031
  • 3.5 IMMUNOASSAY MARKET, BY APPLICATION, 2026 VS. 2031
  • 3.6 IMMUNOASSAY MARKET, BY END USER, 2026 VS. 2031
  • 3.7 IMMUNOASSAY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Increasing incidence of chronic and infectious diseases
        • 4.2.1.1.1 Increased use of immunoassays in oncology
        • 4.2.1.1.2 Rising use of immunoassays in diagnostic applications
        • 4.2.1.1.3 High geriatric population
      • 4.2.1.2 Increased demand for blood donations in healthcare systems and surgical procedures
      • 4.2.1.3 Growth in biotechnology & biopharmaceutical industries
      • 4.2.1.4 Increasing adoption of immunoassay-based POC and rapid testing
      • 4.2.1.5 Supportive government regulatory policies and initiatives
      • 4.2.1.6 Increased consumption of drugs, alcohol, and cannabis
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 Stringent requirements for approval of immunoassay instruments and consumables
      • 4.2.2.2 Technical hurdles of immunoassay kits
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Increasing growth opportunities in emerging economies
      • 4.2.3.2 Focus on importance of companion diagnostics
      • 4.2.3.3 Development of condition-specific biomarkers and tests
      • 4.2.3.4 Integration of microfluidics in immunoassays
      • 4.2.3.5 Improving immunoassay diagnostic technologies
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Design challenges and low quality of antibodies
      • 4.2.4.2 Dearth of skilled professionals
  • 4.3 UNMET NEEDS & WHITE SPACES
    • 4.3.1 UNMET NEEDS IN IMMUNOASSAY MARKET
    • 4.3.2 WHITE SPACE OPPORTUNITIES
  • 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
    • 4.4.1 INTERCONNECTED MARKETS
    • 4.4.2 CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
    • 4.5.1 KEY MOVES AND STRATEGIC FOCUS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.1.2 BARGAINING POWER OF SUPPLIERS
    • 5.1.3 BARGAINING POWER OF BUYERS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 THREAT OF NEW ENTRANTS
  • 5.2 MACROECONOMIC INDICATORS
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS & FORECAST
  • 5.3 SUPPLY CHAIN ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 PRICING ANALYSIS
    • 5.6.1 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY KEY PLAYER, 2024-2026
    • 5.6.2 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY ANALYZERS, BY REGION, 2024-2026
    • 5.6.3 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY TYPE, 2024-2026
  • 5.7 TRADE ANALYSIS
    • 5.7.1 IMPORT SCENARIO (HS CODE 382200)
    • 5.7.2 EXPORT SCENARIO (HS CODE 382200)
  • 5.8 KEY CONFERENCES & EVENTS, 2026-2027
  • 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.10 INVESTMENT & FUNDING SCENARIO
  • 5.11 IMPACT OF 2025 US TARIFFS ON IMMUNOASSAY MARKET
    • 5.11.1 INTRODUCTION
    • 5.11.2 KEY TARIFF RATES
    • 5.11.3 PRICE IMPACT ANALYSIS
    • 5.11.4 IMPACT ON COUNTRY/REGION
      • 5.11.4.1 North America
        • 5.11.4.1.1 US
      • 5.11.4.2 Europe
        • 5.11.4.2.1 Germany
        • 5.11.4.2.2 UK and France
      • 5.11.4.3 Asia Pacific
        • 5.11.4.3.1 China
        • 5.11.4.3.2 Japan
        • 5.11.4.3.3 India
    • 5.11.5 IMPACT ON END-USE INDUSTRIES
      • 5.11.5.1 Hospitals & clinics
      • 5.11.5.2 Clinical laboratories
      • 5.11.5.3 Blood banks
      • 5.11.5.4 Home care settings

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1 ELISA
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    • 6.2.1 LATERAL FLOW ASSAYS
  • 6.3 ADJACENT TECHNOLOGIES
    • 6.3.1 MICROFLUIDICS & MINIATURIZED PLATFORMS
  • 6.4 TECHNOLOGY/PRODUCT ROADMAP
  • 6.5 PATENT ANALYSIS
    • 6.5.1 LIST OF MAJOR PATENTS
  • 6.6 FUTURE APPLICATIONS
  • 6.7 IMPACT OF AI/GEN AI ON IMMUNOASSAY MARKET
    • 6.7.1 MARKET POTENTIAL FOR IMMUNOASSAY PRODUCTS
    • 6.7.2 TOP USE CASES & MARKET POTENTIAL
    • 6.7.3 KEY COMPANIES IMPLEMENTING AI
    • 6.7.4 FUTURE OF AI

7 SUSTAINABILITY & REGULATORY LANDSCAPE

  • 7.1 REGIONAL REGULATIONS & COMPLIANCE
    • 7.1.1 REGULATORY LANDSCAPE
      • 7.1.1.1 North America
        • 7.1.1.1.1 US
        • 7.1.1.1.2 Canada
      • 7.1.1.2 Europe
        • 7.1.1.2.1 Russia
      • 7.1.1.3 Asia Pacific
        • 7.1.1.3.1 Japan
        • 7.1.1.3.2 China
        • 7.1.1.3.3 India
        • 7.1.1.3.4 Indonesia
        • 7.1.1.3.5 South Korea
      • 7.1.1.4 Middle East
        • 7.1.1.4.1 Saudi Arabia
      • 7.1.1.5 Latin America
        • 7.1.1.5.1 Mexico
        • 7.1.1.5.2 Brazil
      • 7.1.1.6 Africa
    • 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.2 SUSTAINABILITY INITIATIVES
    • 7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES IN IMMUNOASSAY MARKET
      • 7.2.1.1 Eco-friendly Initiatives
  • 7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 BUYING CRITERIA
  • 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
  • 8.5 MARKET PROFITABILITY
    • 8.5.1 REVENUE POTENTIAL
    • 8.5.2 COST DYNAMICS
    • 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

9 IMMUNOASSAY MARKET, BY PRODUCT

  • 9.1 INTRODUCTION
  • 9.2 REAGENTS & KITS
    • 9.2.1 ELISA REAGENTS & KITS
      • 9.2.1.1 Increased use of high-throughput screening in drug discovery programs to drive segment
    • 9.2.2 RAPID TEST REAGENTS & KITS
      • 9.2.2.1 High demand for preliminary screening tests in remote areas to propel segment growth
    • 9.2.3 CLIA REAGENTS & KITS
      • 9.2.3.1 Better diagnosis and higher specificity to augment segment growth
    • 9.2.4 IFA REAGENTS & KITS
      • 9.2.4.1 Better adaptability in clinical diagnostics to support segment growth
    • 9.2.5 WESTERN BLOT REAGENTS & KITS
      • 9.2.5.1 Western blot reagents & kits to be considered gold standard for infectious disease test result validation
    • 9.2.6 OTHER REAGENTS & KITS
  • 9.3 ANALYZERS
    • 9.3.1 IMMUNOASSAY ANALYZERS MARKET, BY TYPE
      • 9.3.1.1 Open-ended systems
        • 9.3.1.1.1 Better flexibility and wider availability to drive segment growth
      • 9.3.1.2 Closed-ended systems
        • 9.3.1.2.1 Higher precision and better automation to fuel segment growth
    • 9.3.2 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE
      • 9.3.2.1 Rental purchase
        • 9.3.2.1.1 Increased convenience and reduced liability to boost segment growth
      • 9.3.2.2 Outright purchase
        • 9.3.2.2.1 Inflated cost of immunoassay testing technologies to limit market growth

10 IMMUNOASSAY MARKET, BY TECHNOLOGY

  • 10.1 INTRODUCTION
  • 10.2 ELISA
    • 10.2.1 BETTER SENSITIVITY AND QUICKER RESULTS TO DRIVE MARKET
  • 10.3 CLIA
    • 10.3.1 GOOD SPECIFICITY, WIDE LINEAR RANGE, AND HIGH SENSITIVITY TO AID MARKET GROWTH
  • 10.4 IFA
    • 10.4.1 GROWING USE OF IFA TO DIAGNOSE ANTIBODIES AND ANALYZE SMALL BIOLOGICAL AND NON-BIOLOGICAL MOLECULES TO BOOST GROWTH
  • 10.5 RAPID TESTS
    • 10.5.1 FASTER RESULTS AND EASE OF USE TO DRIVE ADOPTION IN POINT-OF-CARE DIAGNOSIS AND EMERGENCY CARE SETTINGS
  • 10.6 WESTERN BLOTTING
    • 10.6.1 ABILITY TO DETECT AND CONFIRM ANTIBODIES OF RETROVIRUSES TO SPUR MARKET GROWTH
  • 10.7 OTHER TECHNOLOGIES

11 IMMUNOASSAY MARKET, BY SPECIMEN

  • 11.1 INTRODUCTION
  • 11.2 BLOOD
    • 11.2.1 HIGH RELIABILITY AND INCREASED NEED DURING SURGICAL PROCEDURES TO AID MARKET GROWTH
  • 11.3 SALIVA
    • 11.3.1 ADVANCEMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO AUGMENT MARKET GROWTH
  • 11.4 URINE
    • 11.4.1 INCREASING USE BY LAW ENFORCEMENT AGENCIES AND RISING PREVALENCE OF KIDNEY DISEASES TO FAVOR MARKET GROWTH
  • 11.5 OTHER SPECIMENS

12 IMMUNOASSAY MARKET, BY APPLICATION

  • 12.1 INTRODUCTION
  • 12.2 INFECTIOUS DISEASES
    • 12.2.1 RISING PREVALENCE OF CHRONIC INFECTIOUS DISEASES TO DRIVE MARKET
  • 12.3 ENDOCRINOLOGY
    • 12.3.1 RISING INCIDENCE OF DIABETES TO AUGMENT MARKET GROWTH
  • 12.4 CARDIOLOGY
    • 12.4.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO SUPPORT MARKET GROWTH
  • 12.5 AUTOIMMUNE DISORDERS
    • 12.5.1 HIGH INCIDENCE AND PREVALENCE OF AUTOIMMUNE DISEASES TO AUGMENT MARKET GROWTH
  • 12.6 ALLERGY DIAGNOSTICS
    • 12.6.1 GROWING PREVALENCE OF ALLERGIES TO AID MARKET GROWTH
  • 12.7 ONCOLOGY
    • 12.7.1 RISING BURDEN OF CANCER AND GROWING EMPHASIS ON EARLY DETECTION TO PROPEL MARKET GROWTH
  • 12.8 BONE & MINERAL DISORDERS
    • 12.8.1 INCREASING PREVALENCE OF OSTEOPOROSIS, VITAMIN D DEFICIENCY, AND ARTHRITIS TO AID MARKET GROWTH
  • 12.9 DRUG MONITORING & TESTING
    • 12.9.1 RISING DRUG ABUSE AND INCREASING ILLICIT DRUG CONSUMPTION TO ACCELERATE MARKET GROWTH
  • 12.10 BLOOD SCREENING
    • 12.10.1 RISING EMPHASIS ON BLOOD DONATIONS TO FAVOR MARKET GROWTH
  • 12.11 NEWBORN SCREENING
    • 12.11.1 TECHNOLOGICAL ADVANCEMENTS AND FAVORABLE GOVERNMENT INITIATIVES TO PROPEL MARKET GROWTH
  • 12.12 OTHER APPLICATIONS

13 IMMUNOASSAY MARKET, BY END USER

  • 13.1 INTRODUCTION
  • 13.2 HOSPITALS & CLINICS
    • 13.2.1 GROWING PATIENT POPULATION AND RISING TESTING VOLUMES TO DRIVE MARKET
  • 13.3 CLINICAL LABORATORIES
    • 13.3.1 INCREASING NUMBER OF ACCREDITED LABORATORIES TO DRIVE MARKET
  • 13.4 HOME CARE SETTINGS
    • 13.4.1 RISING UTILIZATION OF POC DIAGNOSTICS AND AT-HOME ANTIGEN DIAGNOSIS TO PROPEL MARKET GROWTH
  • 13.5 BLOOD BANKS
    • 13.5.1 INCREASING NUMBER OF ACCIDENTS AND RISING DEMAND FOR BLOOD DURING SURGERIES TO SPUR MARKET GROWTH

14 IMMUNOASSAY MARKET, BY REGION

  • 14.1 INTRODUCTION
  • 14.2 NORTH AMERICA
    • 14.2.1 US
      • 14.2.1.1 US to dominate North American immunoassay market during forecast period
    • 14.2.2 CANADA
      • 14.2.2.1 Increasing government support and rising incidence of chronic diseases to augment market growth
  • 14.3 EUROPE
    • 14.3.1 GERMANY
      • 14.3.1.1 High healthcare spending and favorable government initiatives to propel market growth
    • 14.3.2 ITALY
      • 14.3.2.1 Rising geriatric population and increasing cancer prevalence to spur market growth
    • 14.3.3 FRANCE
      • 14.3.3.1 Increased use of POC testing and favorable reimbursement policies to boost market growth
    • 14.3.4 UK
      • 14.3.4.1 Government support for disease diagnostics and favorable investment scenario to drive market
    • 14.3.5 SPAIN
      • 14.3.5.1 Increasing adoption of technologically advanced immunoassay systems to augment market growth
    • 14.3.6 RUSSIA
      • 14.3.6.1 Increasing access to quality healthcare and developing pharmaceutical industry to favor market growth
    • 14.3.7 REST OF EUROPE
  • 14.4 ASIA PACIFIC
    • 14.4.1 CHINA
      • 14.4.1.1 Increasing government investments and rising geriatric population to accelerate market growth
    • 14.4.2 JAPAN
      • 14.4.2.1 Increasing investments in healthcare technologies and research activities to fuel market growth
    • 14.4.3 INDIA
      • 14.4.3.1 Growing medical tourism and improving healthcare infrastructure to propel market growth
    • 14.4.4 AUSTRALIA
      • 14.4.4.1 Increasing incidence of cancer and rising focus on blood donations to favor market growth
    • 14.4.5 SOUTH KOREA
      • 14.4.5.1 Rising healthcare spending and increasing research investments to fuel market growth
    • 14.4.6 INDONESIA
      • 14.4.6.1 High geriatric population and favorable government healthcare policies to accelerate market growth
    • 14.4.7 REST OF ASIA PACIFIC
  • 14.5 LATIN AMERICA
    • 14.5.1 BRAZIL
      • 14.5.1.1 Growing geriatric population and government investments to accelerate market growth
    • 14.5.2 MEXICO
      • 14.5.2.1 Increasing geriatric population and rising popularity of medical tourism to propel market growth
    • 14.5.3 REST OF LATIN AMERICA
  • 14.6 MIDDLE EAST & AFRICA
    • 14.6.1 LACK OF SKILLED LABORATORY PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT MARKET GROWTH

15 IMMUNOASSAYS MARKET: VOLUME ANALYSIS

  • 15.1 INTRODUCTION
  • 15.2 US: NUMBER OF IN VITRO DIAGNOSTICS TESTS CONDUCTED, 2024-2031 (BILLION UNITS)

16 COMPETITIVE LANDSCAPE

  • 16.1 INTRODUCTION
  • 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 16.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN IMMUNOASSAY MARKET
  • 16.3 REVENUE ANALYSIS, 2023-2025
  • 16.4 MARKET SHARE ANALYSIS, 2025
    • 16.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
  • 16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 16.5.1 STARS
    • 16.5.2 EMERGING LEADERS
    • 16.5.3 PERVASIVE PLAYERS
    • 16.5.4 PARTICIPANTS
    • 16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 16.5.5.1 Company footprint
      • 16.5.5.2 Region footprint
      • 16.5.5.3 Product footprint
      • 16.5.5.4 Specimen footprint
  • 16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 16.6.1 PROGRESSIVE COMPANIES
    • 16.6.2 RESPONSIVE COMPANIES
    • 16.6.3 DYNAMIC COMPANIES
    • 16.6.4 STARTING BLOCKS
    • 16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
      • 16.6.5.1 List of key startups/SMEs
      • 16.6.5.2 Competitive benchmarking of key startups/SMEs
  • 16.7 COMPANY VALUATION & FINANCIAL METRICS
    • 16.7.1 FINANCIAL METRICS
    • 16.7.2 COMPANY VALUATION
  • 16.8 BRAND/PRODUCT COMPARISON
  • 16.9 COMPETITIVE SCENARIO
    • 16.9.1 PRODUCT LAUNCHES & APPROVALS
    • 16.9.2 DEALS
    • 16.9.3 EXPANSIONS

17 COMPANY PROFILES

  • 17.1 KEY PLAYERS
    • 17.1.1 ABBOTT
      • 17.1.1.1 Business overview
      • 17.1.1.2 Products offered
      • 17.1.1.3 Recent developments
        • 17.1.1.3.1 Product launches & approvals
        • 17.1.1.3.2 Deals
        • 17.1.1.3.3 Expansions
      • 17.1.1.4 MnM view
        • 17.1.1.4.1 Right to win
        • 17.1.1.4.2 Strategic choices
        • 17.1.1.4.3 Weaknesses & competitive threats
    • 17.1.2 F. HOFFMANN-LA ROCHE LTD.
      • 17.1.2.1 Business overview
      • 17.1.2.2 Products offered
      • 17.1.2.3 Recent developments
        • 17.1.2.3.1 Product launches & approvals
        • 17.1.2.3.2 Deals
        • 17.1.2.3.3 Expansions
      • 17.1.2.4 MnM view
        • 17.1.2.4.1 Right to win
        • 17.1.2.4.2 Strategic choices
        • 17.1.2.4.3 Weaknesses & competitive threats
    • 17.1.3 SIEMENS HEALTHINEERS AG
      • 17.1.3.1 Business overview
      • 17.1.3.2 Products offered
      • 17.1.3.3 Recent developments
        • 17.1.3.3.1 Product launches & approvals
        • 17.1.3.3.2 Deals
        • 17.1.3.3.3 Expansions
      • 17.1.3.4 MnM view
        • 17.1.3.4.1 Right to win
        • 17.1.3.4.2 Strategic choices
        • 17.1.3.4.3 Weaknesses & competitive threats
    • 17.1.4 DANAHER CORPORATION
      • 17.1.4.1 Business overview
      • 17.1.4.2 Products offered
      • 17.1.4.3 Recent developments
        • 17.1.4.3.1 Product launches & approvals
        • 17.1.4.3.2 Deals
        • 17.1.4.3.3 Expansions
      • 17.1.4.4 MnM view
        • 17.1.4.4.1 Right to win
        • 17.1.4.4.2 Strategic choices
        • 17.1.4.4.3 Weaknesses & competitive threats
    • 17.1.5 THERMO FISHER SCIENTIFIC INC.
      • 17.1.5.1 Business overview
      • 17.1.5.2 Products offered
      • 17.1.5.3 Recent developments
        • 17.1.5.3.1 Product launches & approvals
        • 17.1.5.3.2 Deals
      • 17.1.5.4 MnM view
        • 17.1.5.4.1 Right to win
        • 17.1.5.4.2 Strategic choices
        • 17.1.5.4.3 Weaknesses & competitive threats
    • 17.1.6 REVVITY INC.
      • 17.1.6.1 Business overview
      • 17.1.6.2 Products offered
      • 17.1.6.3 Recent developments
        • 17.1.6.3.1 Product launches & approvals
        • 17.1.6.3.2 Other developments
    • 17.1.7 WATERS CORPORATION
      • 17.1.7.1 Business overview
      • 17.1.7.2 Products offered
      • 17.1.7.3 Recent developments
        • 17.1.7.3.1 Deals
    • 17.1.8 DIASORIN S.P.A.
      • 17.1.8.1 Business overview
      • 17.1.8.2 Products offered
      • 17.1.8.3 Recent developments
        • 17.1.8.3.1 Product launches & approvals
        • 17.1.8.3.2 Deals
    • 17.1.9 BIO-RAD LABORATORIES, INC.
      • 17.1.9.1 Business overview
      • 17.1.9.2 Products offered
      • 17.1.9.3 Recent developments
        • 17.1.9.3.1 Product launches
        • 17.1.9.3.2 Deals
    • 17.1.10 QUIDELORTHO CORPORATION
      • 17.1.10.1 Business overview
      • 17.1.10.2 Products offered
      • 17.1.10.3 Recent developments
        • 17.1.10.3.1 Product launches & approvals
        • 17.1.10.3.2 Expansions
    • 17.1.11 BIOMERIEUX
      • 17.1.11.1 Business overview
      • 17.1.11.2 Products offered
      • 17.1.11.3 Recent developments
        • 17.1.11.3.1 Product launches & approvals
        • 17.1.11.3.2 Deals
    • 17.1.12 QIAGEN
      • 17.1.12.1 Business overview
      • 17.1.12.2 Products offered
      • 17.1.12.3 Recent developments
        • 17.1.12.3.1 Deals
    • 17.1.13 SYSMEX CORPORATION
      • 17.1.13.1 Business overview
      • 17.1.13.2 Products offered
      • 17.1.13.3 Recent developments
        • 17.1.13.3.1 Product launches
        • 17.1.13.3.2 Deals
        • 17.1.13.3.3 Expansions
    • 17.1.14 AGILENT TECHNOLOGIES, INC.
      • 17.1.14.1 Business overview
      • 17.1.14.2 Products offered
      • 17.1.14.3 Recent developments
        • 17.1.14.3.1 Product approvals
        • 17.1.14.3.2 Deals
    • 17.1.15 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
      • 17.1.15.1 Business overview
      • 17.1.15.2 Products offered
      • 17.1.15.3 Recent developments
        • 17.1.15.3.1 Product launches
  • 17.2 OTHER PLAYERS
    • 17.2.1 MERCK KGAA
    • 17.2.2 MERIDIAN BIOSCIENCE
    • 17.2.3 BIO-TECHNE
    • 17.2.4 CELLABS
    • 17.2.5 ABNOVA CORPORATION
    • 17.2.6 J. MITRA & CO. PVT. LTD.
    • 17.2.7 TOSOH CORPORATION (TOSOH BIOSCIENCES)
    • 17.2.8 CELL SCIENCES
    • 17.2.9 ENZO BIOCHEM INC.
    • 17.2.10 CREATIVE DIAGNOSTICS
    • 17.2.11 BOSTER BIOLOGICAL TECHNOLOGY
    • 17.2.12 ELABSCIENCE BIONOVATION INC.
    • 17.2.13 WAK-CHEMIE MEDICAL GMBH
    • 17.2.14 SERA CARE
    • 17.2.15 EPITOPE DIAGNOSTICS, INC.
    • 17.2.16 KAMIYA BIOMEDICAL COMPANY
    • 17.2.17 GYROS PROTEIN TECHNOLOGIES AB
    • 17.2.18 TRIVITRON HEALTHCARE
    • 17.2.19 INBIOS INTERNATIONAL, INC.
    • 17.2.20 MACCURA BIOTECHNOLOGY CO., LTD.

18 RESEARCH METHODOLOGY

  • 18.1 RESEARCH DATA
    • 18.1.1 SECONDARY RESEARCH
      • 18.1.1.1 Key secondary sources
      • 18.1.1.2 Key data from secondary sources
    • 18.1.2 PRIMARY RESEARCH
      • 18.1.2.1 Key primary sources
      • 18.1.2.2 Key objectives of primary research
      • 18.1.2.3 Key data from primary sources
      • 18.1.2.4 Key industry insights
  • 18.2 MARKET SIZE ESTIMATION
    • 18.2.1 BOTTOM-UP APPROACH
    • 18.2.2 COMPANY PRESENTATIONS & PRIMARY INTERVIEWS
    • 18.2.3 TOP-DOWN APPROACH
  • 18.3 DATA TRIANGULATION
  • 18.4 MARKET SHARE ANALYSIS
  • 18.5 STUDY ASSUMPTIONS
    • 18.5.1 MARKET ASSUMPTIONS
    • 18.5.2 GROWTH RATE ASSUMPTIONS
  • 18.6 RESEARCH LIMITATIONS
    • 18.6.1 METHODOLOGY-RELATED LIMITATIONS
    • 18.6.2 SCOPE-RELATED LIMITATIONS
  • 18.7 RISK ANALYSIS

19 APPENDIX

  • 19.1 DISCUSSION GUIDE
  • 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 19.3 CUSTOMIZATION OPTIONS
  • 19.4 RELATED REPORTS
  • 19.5 AUTHOR DETAILS
Product Code: MD 4751

List of Tables

  • TABLE 1 IMMUNOASSAY MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2024 VS. 2040 (MILLION)
  • TABLE 3 NUMBER OF NEW CANCER CASES, BY CANCER TYPE, 2024
  • TABLE 4 DETECTION TIME OF DRUG OR DRUG CLASS IN URINE TESTING
  • TABLE 5 NEW TESTS LAUNCHED BY KEY PLAYERS, 2023-2026
  • TABLE 6 LAB-ON-CHIP IMMUNOASSAYS/DEVICES/SYSTEMS OFFERED BY KEY PLAYERS
  • TABLE 7 IMMUNOASSAY MARKET: PORTER'S FIVE FORCES
  • TABLE 8 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023-2030
  • TABLE 9 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 10 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 11 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 12 LATIN AMERICA: MACROECONOMIC INDICATORS
  • TABLE 13 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
  • TABLE 14 IMMUNOASSAY MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 15 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY KEY PLAYER, 2024-2026 (USD)
  • TABLE 16 AVERAGE SELLING PRICE TREND OF CLINICAL IMMUNOASSAY ANALYZERS, BY REGION, 2024-2026 (USD)
  • TABLE 17 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY TYPE, 2024-2026 (USD)
  • TABLE 18 IMPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD MILLION)
  • TABLE 19 EXPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD MILLION)
  • TABLE 20 IMMUNOASSAY MARKET: KEY CONFERENCES & EVENTS, 2026-2027
  • TABLE 21 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 22 KEY PATENTS IN IMMUNOASSAY, 2023-2026
  • TABLE 23 KEY COMPANIES IMPLEMENTING AI IN IMMUNOASSAY MARKET
  • TABLE 24 US: CLASSIFICATION AND RISK LEVEL OF IMMUNOASSAY PRODUCTS
  • TABLE 25 EUROPE: CLASSIFICATION AND RISK LEVEL OF IN VITRO DIAGNOSTIC DEVICES
  • TABLE 26 RUSSIA: CLASSIFICATION AND RISK LEVEL OF IN VITRO DIAGNOSTIC DEVICES
  • TABLE 27 JAPAN: CLASSIFICATION OF IN VITRO DIAGNOSTIC REAGENTS
  • TABLE 28 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 29 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 30 INDONESIA: REGISTRATION PROCESS FOR IN VITRO DIAGNOSTIC DEVICES
  • TABLE 31 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 32 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 33 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 34 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 35 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 36 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 37 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 38 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 39 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)
  • TABLE 40 KEY BUYING CRITERIA, BY END USER
  • TABLE 41 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • TABLE 42 IMMUNOASSAY MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
  • TABLE 43 IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 44 KEY REAGENTS & KITS AVAILABLE IN MARKET
  • TABLE 45 IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 46 IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 47 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 48 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 49 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 50 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 51 ELISA REAGENTS & KITS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 52 NORTH AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 53 EUROPE: ELISA REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 54 ASIA PACIFIC: ELISA REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 55 LATIN AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 56 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 57 NORTH AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 58 EUROPE: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 59 ASIA PACIFIC: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 60 LATIN AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 61 CLIA REAGENTS & KITS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 62 NORTH AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 63 EUROPE: CLIA REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 64 ASIA PACIFIC: CLIA REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 65 LATIN AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 66 IFA REAGENTS & KITS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 67 NORTH AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 68 EUROPE: IFA REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 69 ASIA PACIFIC: IFA REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 70 LATIN AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 71 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 72 NORTH AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 73 EUROPE: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 74 ASIA PACIFIC: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 75 LATIN AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 76 OTHER REAGENTS & KITS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 77 NORTH AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 78 EUROPE: OTHER REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 79 ASIA PACIFIC: OTHER REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 80 LATIN AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 81 KEY ANALYZERS AVAILABLE IN MARKET
  • TABLE 82 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 83 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 84 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 85 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 86 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 87 IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 88 OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 89 NORTH AMERICA: OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 90 EUROPE: OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 91 ASIA PACIFIC: OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 92 LATIN AMERICA: OPEN-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 93 CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 94 NORTH AMERICA: CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 95 EUROPE: CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 96 ASIA PACIFIC: CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 97 LATIN AMERICA: CLOSED-ENDED IMMUNOASSAY SYSTEMS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 98 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 99 IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 100 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 101 EUROPE: IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 102 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 103 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 104 IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 105 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 106 EUROPE: IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 107 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 108 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 109 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 110 KEY ELISA TECHNOLOGIES AVAILABLE IN MARKET
  • TABLE 111 IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 112 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 113 EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 114 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 115 LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 116 IMMUNOASSAY MARKET FOR CLIA, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 117 NORTH AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 118 EUROPE: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 120 LATIN AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 121 IMMUNOASSAY MARKET FOR IFA, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 122 NORTH AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 123 EUROPE: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 124 ASIA PACIFIC: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 125 LATIN AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 126 KEY RAPID TESTS AVAILABLE IN MARKET
  • TABLE 127 IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 128 NORTH AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 129 EUROPE: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 130 ASIA PACIFIC: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 131 LATIN AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 132 KEY WESTERN BLOTTING SYSTEMS AVAILABLE IN MARKET
  • TABLE 133 IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 134 NORTH AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 135 EUROPE: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 136 ASIA PACIFIC: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 137 LATIN AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 138 IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 139 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 140 EUROPE: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 141 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 142 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 143 IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 144 IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 145 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 146 EUROPE: IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 147 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 148 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 149 IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 150 NORTH AMERICA: IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 151 EUROPE: IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 152 ASIA PACIFIC: IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 153 LATIN AMERICA: IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 154 IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 155 NORTH AMERICA: IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 156 EUROPE: IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 157 ASIA PACIFIC: IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 158 LATIN AMERICA: IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 159 IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 160 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 161 EUROPE: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 162 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 163 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 164 IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 165 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 166 NORTH AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 167 EUROPE: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 168 ASIA PACIFIC: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 169 LATIN AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 170 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 171 NORTH AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 172 EUROPE: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 173 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 174 LATIN AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 175 KEY PRODUCTS AVAILABLE FOR CARDIOLOGY APPLICATIONS
  • TABLE 176 IMMUNOASSAY MARKET FOR CARDIOLOGY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 177 NORTH AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 178 EUROPE: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 179 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 180 LATIN AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 181 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 182 NORTH AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 183 EUROPE: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 184 ASIA PACIFIC: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 185 LATIN AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 186 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 187 NORTH AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 188 EUROPE: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 189 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 190 LATIN AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 191 IMMUNOASSAY MARKET FOR ONCOLOGY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 192 NORTH AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 193 EUROPE: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 194 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 195 LATIN AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 196 KEY PRODUCTS AVAILABLE FOR BONE & MINERAL DISORDERS
  • TABLE 197 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 198 NORTH AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 199 EUROPE: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 200 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 201 LATIN AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 202 KEY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING
  • TABLE 203 KEY IMMUNOASSAY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING
  • TABLE 204 IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 205 NORTH AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 206 EUROPE: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 207 ASIA PACIFIC: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 208 LATIN AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 209 IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 210 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 211 EUROPE: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 212 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 213 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 214 KEY PRODUCTS AVAILABLE FOR NEWBORN SCREENING
  • TABLE 215 IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 216 NORTH AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 217 EUROPE: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 218 ASIA PACIFIC: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 219 LATIN AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 220 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 221 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 222 EUROPE: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 223 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 224 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 225 IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 226 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 227 NORTH AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 228 EUROPE: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 229 ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 230 LATIN AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 231 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 232 NORTH AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 233 EUROPE: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 234 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 235 LATIN AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 236 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 237 NORTH AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 238 EUROPE: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 239 ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 240 LATIN AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 241 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 242 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 243 EUROPE: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 244 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 245 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 246 IMMUNOASSAY MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 247 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 248 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 249 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 250 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 251 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 252 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 253 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 254 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 255 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 256 US: NUMBER OF IN VITRO DIAGNOSTIC TESTS CONDUCTED, 2022-2031 (BILLION UNITS)
  • TABLE 257 US: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 258 US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 259 US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 260 US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 261 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 262 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 263 US: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 264 US: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 265 CANADA: ESTIMATED PREVALENCE OF DIABETES, 2025 VS. 2034
  • TABLE 266 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 267 CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 268 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 269 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 270 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 271 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 272 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 273 CANADA: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 274 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 275 EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 276 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 277 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 278 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 279 EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 280 EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 281 EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 282 EUROPE: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 283 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 284 GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 285 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 286 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 287 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 288 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 289 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 290 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 291 ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 292 ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 293 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 294 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 295 ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 296 ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 297 ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 298 ITALY: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 299 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 300 FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 301 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 302 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 303 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 304 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 305 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 306 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 307 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 308 UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 309 UK: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 310 UK: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 311 UK: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 312 UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 313 UK: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 314 UK: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 315 SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 316 SPAIN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 317 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 318 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 319 SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 320 SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 321 SPAIN: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 322 SPAIN: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 323 RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 324 RUSSIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 325 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 326 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 327 RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 328 RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 329 RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 330 RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 331 REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 332 REST OF EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 333 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 334 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 335 REST OF EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 336 REST OF EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 337 REST OF EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 338 REST OF EUROPE: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 339 MACROECONOMIC INDICATORS FOR ASIA PACIFIC
  • TABLE 340 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 341 ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 342 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 343 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 344 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 345 ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 346 ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 347 ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 348 ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 349 CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 350 CHINA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 351 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 352 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 353 CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 354 CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 355 CHINA: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 356 CHINA: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 357 JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 358 JAPAN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 359 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 360 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 361 JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 362 JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 363 JAPAN: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 364 JAPAN: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 365 INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 366 INDIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 367 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 368 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 369 INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 370 INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 371 INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 372 INDIA: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 373 AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 374 AUSTRALIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 375 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 376 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 377 AUSTRALIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 378 AUSTRALIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 379 AUSTRALIA: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 380 AUSTRALIA: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 381 SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 382 SOUTH KOREA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 383 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 384 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 385 SOUTH KOREA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 386 SOUTH KOREA: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 387 SOUTH KOREA: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 388 SOUTH KOREA: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 389 INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 390 INDONESIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 391 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 392 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 393 INDONESIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 394 INDONESIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 395 INDONESIA: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 396 INDONESIA: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 397 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 398 REST OF ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 399 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 400 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 401 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 402 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 403 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 404 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 405 MACROECONOMIC INDICATORS FOR LATIN AMERICA
  • TABLE 406 LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 407 LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 408 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 409 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 410 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 411 LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 412 LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 413 LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 414 LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 415 BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 416 BRAZIL: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 417 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 418 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 419 BRAZIL: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 420 BRAZIL: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 421 BRAZIL: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 422 BRAZIL: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 423 MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 424 MEXICO: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 425 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 426 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 427 MEXICO: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 428 MEXICO: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 429 MEXICO: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 430 MEXICO: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 431 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 432 REST OF LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 433 REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 434 REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 435 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 436 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 437 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 438 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 439 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 440 MIDDLE EAST & AFRICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 441 MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 442 MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2024-2031 (USD MILLION)
  • TABLE 443 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 444 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2024-2031 (USD MILLION)
  • TABLE 445 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 446 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 447 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN IMMUNOASSAY MARKET, JANUARY 2023-AUGUST 2026
  • TABLE 448 IMMUNOASSAY MARKET: DEGREE OF COMPETITION
  • TABLE 449 IMMUNOASSAY MARKET: REGION FOOTPRINT
  • TABLE 450 IMMUNOASSAY MARKET: PRODUCT FOOTPRINT
  • TABLE 451 IMMUNOASSAY MARKET: SPECIMEN FOOTPRINT
  • TABLE 452 IMMUNOASSAY MARKET: LIST OF KEY STARTUPS/SME PLAYERS
  • TABLE 453 IMMUNOASSAY MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS, BY REGION
  • TABLE 454 IMMUNOASSAY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-AUGUST 2026
  • TABLE 455 IMMUNOASSAY MARKET: DEALS, JANUARY 2023-AUGUST 2026
  • TABLE 456 IMMUNOASSAY MARKET: EXPANSION, JANUARY 2023-AUGUST 2026
  • TABLE 457 ABBOTT: COMPANY OVERVIEW
  • TABLE 458 ABBOTT: PRODUCTS OFFERED
  • TABLE 459 ABBOTT: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 460 ABBOTT: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 461 ABBOTT: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 462 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 463 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
  • TABLE 464 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 465 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 466 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 467 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 468 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
  • TABLE 469 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 470 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 471 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 472 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 473 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 474 DANAHER CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 475 DANAHER CORPORATION: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 476 DANAHER CORPORATION: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 477 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 478 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 479 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 480 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 481 REVVITY INC.: COMPANY OVERVIEW
  • TABLE 482 REVVITY INC.: PRODUCTS OFFERED
  • TABLE 483 REVVITY INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 484 REVVITY INC.: OTHER DEVELOPMENTS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 485 WATERS CORPORATION: COMPANY OVERVIEW
  • TABLE 486 WATERS CORPORATION: PRODUCTS OFFERED
  • TABLE 487 WATERS CORPORATION: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 488 DIASORIN S.P.A.: COMPANY OVERVIEW
  • TABLE 489 DIASORIN S.P.A.: PRODUCTS OFFERED
  • TABLE 490 DIASORIN S.P.A.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 491 DIASORIN S.P.A.: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 492 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 493 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
  • TABLE 494 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 495 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 496 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
  • TABLE 497 QUIDELORTHO CORPORATION: PRODUCTS OFFERED
  • TABLE 498 QUIDELORTHO CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 499 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 500 BIOMERIEUX: COMPANY OVERVIEW
  • TABLE 501 BIOMERIEUX: PRODUCTS OFFERED
  • TABLE 502 BIOMERIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 503 BIOMERIEUX: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 504 QIAGEN: COMPANY OVERVIEW
  • TABLE 505 QIAGEN: PRODUCTS OFFERED
  • TABLE 506 QIAGEN: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 507 SYSMEX CORPORATION: COMPANY OVERVIEW
  • TABLE 508 SYSMEX CORPORATION: PRODUCTS OFFERED
  • TABLE 509 SYSMEX CORPORATION: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 510 SYSMEX CORPORATION: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 511 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 512 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 513 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
  • TABLE 514 AGILENT TECHNOLOGIES, INC.: PRODUCT APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 515 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 516 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW
  • TABLE 517 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED
  • TABLE 518 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 519 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 520 MERIDIAN BIOSCIENCE: COMPANY OVERVIEW
  • TABLE 521 BIO-TECHNE: COMPANY OVERVIEW
  • TABLE 522 CELLABS: COMPANY OVERVIEW
  • TABLE 523 ABNOVA CORPORATION: COMPANY OVERVIEW
  • TABLE 524 J. MITRA & CO. PVT. LTD.: COMPANY OVERVIEW
  • TABLE 525 TOSOH CORPORATION (TOSOH BIOSCIENCES): COMPANY OVERVIEW
  • TABLE 526 CELL SCIENCES: COMPANY OVERVIEW
  • TABLE 527 ENZO BIOCHEM INC.: COMPANY OVERVIEW
  • TABLE 528 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 529 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW
  • TABLE 530 ELABSCIENCE BIONOVATION INC.: COMPANY OVERVIEW
  • TABLE 531 WAK-CHEMIE MEDICAL GMBH: COMPANY OVERVIEW
  • TABLE 532 SERA CARE: COMPANY OVERVIEW
  • TABLE 533 EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW
  • TABLE 534 KAMIYA BIOMEDICAL COMPANY: COMPANY OVERVIEW
  • TABLE 535 GYROS PROTEIN TECHNOLOGIES AB: COMPANY OVERVIEW
  • TABLE 536 TRIVITRON HEALTHCARE: COMPANY OVERVIEW
  • TABLE 537 INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW
  • TABLE 538 MACCURA BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW
  • TABLE 539 IMMUNOASSAY MARKET: KEY DATA FROM PRIMARY SOURCES
  • TABLE 540 IMMUNOASSAY MARKET: MARKET ASSUMPTIONS
  • TABLE 541 IMMUNOASSAY MARKET: RISK ANALYSIS

List of Figures

  • FIGURE 1 IMMUNOASSAY MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 IMMUNOASSAY MARKET: YEARS CONSIDERED
  • FIGURE 3 KEY INSIGHTS & MARKET HIGHLIGHTS
  • FIGURE 4 GLOBAL IMMUNOASSAY MARKET, 2024-2031
  • FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOASSAY MARKET, 2024-2026
  • FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF IMMUNOASSAY MARKET
  • FIGURE 7 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN IMMUNOASSAY MARKET, 2025
  • FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 9 HIGH PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET
  • FIGURE 10 REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 11 CLIA SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 12 BLOOD SAMPLES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 13 INFECTIOUS DISEASES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 14 HOSPITALS & CLINICS SEGMENT TO COMMAND LARGEST SHARE DURING FORECAST PERIOD
  • FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 16 IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 17 IMMUNOASSAY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 18 IMMUNOASSAY MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 19 IMMUNOASSAY MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 20 IMMUNOASSAY MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 21 IMMUNOASSAY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 22 NUMBER OF DEALS & FUNDING ACTIVITIES IN IMMUNOASSAY MARKET
  • FIGURE 23 TOP 10 PATENT OWNERS/APPLICANTS IN IMMUNOASSAY MARKET, JANUARY 2015-DECEMBER 2024
  • FIGURE 24 MARKET POTENTIAL OF AI IN IMMUNOASSAY MARKET
  • FIGURE 25 US: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES
  • FIGURE 26 CANADA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES
  • FIGURE 27 JAPAN: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES
  • FIGURE 28 INDIA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES
  • FIGURE 29 MEXICO: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES
  • FIGURE 30 BRAZIL: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES
  • FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
  • FIGURE 32 KEY BUYING CRITERIA, BY END USER
  • FIGURE 33 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT
  • FIGURE 34 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT
  • FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNOASSAY MARKET, 2023-2025 (USD MILLION)
  • FIGURE 36 IMMUNOASSAY MARKET SHARE ANALYSIS, 2025 (GLOBAL)
  • FIGURE 37 IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 38 IMMUNOASSAY MARKET: COMPANY FOOTPRINT
  • FIGURE 39 IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 40 EV/EBITDA OF KEY VENDORS
  • FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 42 IMMUNOASSAY MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 43 ABBOTT: COMPANY SNAPSHOT (2025)
  • FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025)
  • FIGURE 45 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025)
  • FIGURE 46 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 48 REVVITY INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 49 WATERS CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 50 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025)
  • FIGURE 51 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 52 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 53 BIOMERIEUX: COMPANY SNAPSHOT (2025)
  • FIGURE 54 QIAGEN: COMPANY SNAPSHOT (2025)
  • FIGURE 55 SYSMEX CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 56 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 57 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2025)
  • FIGURE 58 IMMUNOASSAY MARKET: RESEARCH DESIGN
  • FIGURE 59 IMMUNOASSAY MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 60 IMMUNOASSAY MARKET: KEY PRIMARY SOURCES
  • FIGURE 61 IMMUNOASSAY MARKET: KEY INSIGHTS FROM INDUSTRY EXPERTS
  • FIGURE 62 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 63 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 64 IMMUNOASSAY MARKET: COMPANY REVENUE ESTIMATION (REVENUE SHARE ANALYSIS)
  • FIGURE 65 IMMUNOASSAY MARKET: CAGR PROJECTIONS (SUPPLY-SIDE ANALYSIS)
  • FIGURE 66 IMMUNOASSAY MARKET: TOP-DOWN APPROACH
  • FIGURE 67 IMMUNOASSAY MARKET: DATA TRIANGULATION METHODOLOGY
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!